#1 Clinical Trials Search in Europe

Fingolimod

Fingolimod, also known by the brand name Gilenya, is a medication that has been the subject of numerous clinical trials exploring its efficacy and safety in treating multiple sclerosis (MS) and other conditions. This article summarizes key findings from recent clinical trials investigating fingolimod’s potential benefits, side effects, and long-term outcomes in patients with relapsing forms of MS and other neurological disorders.

Table of Contents

What is Fingolimod?

Fingolimod is a medication primarily used to treat multiple sclerosis (MS). It’s also known by the brand names Gilenya and Imsera[1]. Fingolimod is classified as a sphingosine-1-phosphate receptor modulator, which means it works by affecting certain receptors in your body’s immune system[2].

What Conditions Does Fingolimod Treat?

Fingolimod is primarily used to treat:

  • Relapsing-Remitting Multiple Sclerosis (RRMS): This is the most common form of MS, characterized by periods of symptom flare-ups followed by periods of recovery[3].
  • Other forms of relapsing MS: This includes active secondary progressive MS in adults[1].
Additionally, researchers are exploring its potential use in other conditions:
  • Rett Syndrome: A rare genetic neurological disorder that affects brain development, typically in girls[4].
  • Prevention of chemotherapy-induced nerve pain (neuropathy) in breast cancer patients receiving paclitaxel treatment[5].
  • Acute Ischemic Stroke: When used in combination with other treatments[2].

How Does Fingolimod Work?

Fingolimod works by modulating the immune system. Here’s a simplified explanation of its mechanism:

  1. It binds to receptors called sphingosine-1-phosphate receptors on certain immune cells (lymphocytes).
  2. This binding prevents these immune cells from leaving the lymph nodes.
  3. As a result, fewer immune cells can enter the central nervous system (brain and spinal cord).
  4. This reduction in immune cell activity in the central nervous system helps to decrease inflammation and damage to nerve cells in MS patients[6].
In simpler terms, fingolimod acts like a traffic controller, keeping potentially harmful immune cells from reaching areas where they could cause damage in MS patients.

How is Fingolimod Administered?

Fingolimod is typically administered as follows:

  • It’s taken orally (by mouth) as a capsule.
  • The usual dose is 0.5 mg once daily.
  • It can be taken with or without food[3].
It’s important to note that the first dose of fingolimod is usually given under medical supervision. This is because it can cause a temporary slowing of the heart rate in some patients[7].

Effectiveness of Fingolimod

Clinical trials have shown that fingolimod can be effective in treating relapsing forms of MS. Here are some key findings:

  • It can reduce the frequency of MS relapses (flare-ups of symptoms)[1].
  • It may slow down the progression of disability in MS patients[1].
  • It can reduce the number of new or enlarging brain lesions seen on MRI scans[1].
Studies have also shown that many patients report improved quality of life and satisfaction with treatment when using fingolimod[3].

Potential Side Effects and Safety Considerations

Like all medications, fingolimod can cause side effects. Some potential side effects include:

  • Slowed heart rate, especially after the first dose[7].
  • Increased risk of infections, due to its effects on the immune system[2].
  • Macular edema (swelling in the back of the eye)[2].
  • Elevated liver enzymes[8].
  • Decreased lymphocyte count (a type of white blood cell)[8].
Due to these potential side effects, patients taking fingolimod need regular medical check-ups and monitoring. It’s also important to note that fingolimod may not be suitable for everyone, particularly those with certain heart conditions or pregnant women[9].

Ongoing Research and Future Applications

Researchers continue to study fingolimod to better understand its effects and explore its potential in treating other conditions. Some areas of ongoing research include:

  • Its potential use in treating acute ischemic stroke when combined with other treatments[2].
  • Its effects on cytokine and chemokine levels in MS patients. Cytokines and chemokines are small proteins important in cell signaling and immune responses[6].
  • Its potential in preventing chemotherapy-induced nerve pain in breast cancer patients[5].
  • Its possible benefits in treating Rett Syndrome[4].
These ongoing studies may lead to new applications for fingolimod in the future, potentially benefiting patients with a variety of conditions beyond MS.

Aspect Details
Primary Conditions Studied Relapsing forms of Multiple Sclerosis (MS)
Other Conditions Explored Rett syndrome, stroke, chemotherapy-induced neuropathy
Common Dosage 0.5 mg oral capsule taken once daily
Key Efficacy Measures Annualized relapse rate, disability progression, MRI lesions, brain atrophy
Safety Monitoring Bradycardia, liver function, macular edema, infections, lymphocyte counts
Quality of Life Assessments Treatment satisfaction questionnaires, SF-36 health survey
Trial Durations Range from 6-12 months to long-term extensions of 4-8 years
Special Populations Pregnancy exposure registry, pediatric studies (age 6+)

FAQ

  • What is fingolimod and how does it work? Fingolimod is an oral medication that acts as a modulator of sphingosine-1-phosphate receptors. It works by preventing certain immune cells from leaving the lymph nodes, which reduces inflammation in the central nervous system that can damage nerve cells in multiple sclerosis.
  • What conditions is fingolimod being studied for in clinical trials? While fingolimod is primarily studied for relapsing forms of multiple sclerosis, clinical trials are also exploring its potential in other conditions like Rett syndrome, stroke, and preventing chemotherapy-induced neuropathy in breast cancer patients.
  • What are some of the key outcomes measured in fingolimod clinical trials? Common outcomes measured include relapse rates, disability progression, MRI lesions, brain atrophy, quality of life scores, and various safety parameters. Trials often look at both short-term and long-term efficacy and safety data.
  • Are there any notable side effects or safety concerns with fingolimod? Some potential side effects monitored in trials include bradycardia (slow heart rate), liver function abnormalities, macular edema, and infections. Long-term safety studies are ongoing to further evaluate the drug's risk profile.
  • How long do fingolimod clinical trials typically last? The duration varies, but many trials last 6-12 months for initial efficacy and safety data. Some long-term extension studies have followed patients for several years, up to 4-8 years in some cases, to assess long-term outcomes and safety.

Ongoing Clinical Trials on Fingolimod

  • Study of ublituximab compared to fingolimod for children and teenagers aged 10 to 17 years with relapsing multiple sclerosis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland Slovakia

  • Study Comparing the Effects of Ozanimod and Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland Portugal Romania Spain

  • Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Denmark Estonia +11

  • Study on the Safety and Effectiveness of Fingolimod and Interferon Beta-1a in Children with Multiple Sclerosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Romania Slovakia Spain

  • Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Annualized Relapse Rate (ARR): A measure of the number of relapses a patient experiences per year, used to assess the effectiveness of MS treatments in reducing disease activity.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and practice.
  • Gadolinium-enhanced lesions: Areas of active inflammation in the brain or spinal cord that can be seen on MRI scans when a contrast agent called gadolinium is used. These lesions indicate recent disease activity in MS.
  • T2 lesions: Areas of damage in the brain or spinal cord caused by MS that can be seen on MRI scans. New or enlarging T2 lesions indicate ongoing disease activity.
  • Brain atrophy: The loss of brain tissue volume over time, which can occur at an accelerated rate in MS patients. It is often measured in clinical trials as a marker of disease progression.
  • Quality of life measures: Standardized questionnaires used to assess a patient's overall well-being and satisfaction with treatment, including physical, mental, and social aspects of health.
  • First Dose Observation (FDO): A period of monitoring after the first dose of fingolimod to watch for potential cardiovascular side effects like bradycardia (slow heart rate).
  • Macular edema: Swelling in the macula, the central part of the retina responsible for detailed vision. This is a potential side effect monitored in fingolimod trials.

References

  1. https://clinicaltrials.gov/study/NCT00670449
  2. https://clinicaltrials.gov/study/NCT02956200
  3. https://clinicaltrials.gov/study/NCT01578330
  4. https://clinicaltrials.gov/study/NCT02061137
  5. https://clinicaltrials.gov/study/NCT03941743
  6. https://clinicaltrials.gov/study/NCT02373098
  7. https://clinicaltrials.gov/study/NCT02232061
  8. https://clinicaltrials.gov/study/NCT04480853
  9. https://clinicaltrials.gov/study/NCT01285479